Initiation of oral anticoagulant therapy in orthopedic and surgical patients: an algorithm compared with routine dosing

被引:4
|
作者
van den Bemt, PMLA
Beinema, M
van Roon, EN
Sijtsma, J
Baars, WA
Mencke, HJ
Brouwers, JRBJ
机构
[1] TweeSteden Hosp, Hosp Pharm Midden Brabant, NL-5000 LA Tilburg, Netherlands
[2] St Elizabeth Hosp, Hosp Pharm Midden Brabant, NL-5000 LA Tilburg, Netherlands
[3] Deventer Hosp, Anticoagulant Clin, NL-7400 GC Deventer, Netherlands
[4] Med Centrum Leeuwarden, Hosp Pharm, NL-8901 BR Leeuwarden, Netherlands
[5] Hosp De Tjongerschans Heerenveen, Hosp Pharm, NL-8440 MA Heerenveen, Netherlands
[6] Univ Groningen, Inst Drug Explorat, NL-9713 AV Groningen, Netherlands
[7] Hosp De Tjongerschans Heerenveen, Orthoped Dept, NL-8440 MA Heerenveen, Netherlands
[8] Univ Groningen, Div Pharmacoepidemiol & Drug Policy, Inst Drug Explorat, Dept Pharmacotherapy & Clin Pharm, NL-9713 AV Groningen, Netherlands
关键词
oral anticoagulant; acenocoumarol; initiation; routine dosing; algorithm; hospital;
D O I
10.1007/s00228-002-0477-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oral anticoagulant therapy is initiated in most hospitals in The Netherlands by clinicians who routinely dose oral anticoagulants (without using an algorithm). This may explain the low proportion of patients leaving the hospital stabilized. To test this hypothesis this study compared the dosing of acenocoumarol in orthopedic and surgical patients using an algorithm with routine dosing. Because of the routine administration of low molecular weight heparin for at least the first 5 days of acenocoumarol therapy, the study focused on supra-therapeutic INR-values during this period. The study included 103 patients and was performed on orthopedic surgery and general surgery wards of a Dutch hospital over 5 months. The patients received acenocoumarol as an oral anticoagulant to prevent venous thromboembolism after general of orthopedic surgery. Patients were randomized into a group routinely dosed by physicians (n = 54) and a group dosed using a dosing algorithm (n = 49). A patient was defined as stable if he had two consecutive INR values within the range of 2-3 during hospitalization with the first (of the two consecutive INR values within range) having been measured on day 5 or later. The groups did not differ significantly in proportion of patients stabilized, time to stabilization, or length of hospitalization. In the first period (days 1-5) the routine dosing group had significantly more INR values above therapeutic range than the algorithm group, while the algorithm group had more INR values below the therapeutic range. There were two bleeding episodes in the routine dosing group and none in the algorithm group. Despite the lack of differences in stabilization between the two groups, this study suggests an advantage of dosing acenocoumarol using an algorithm in a study population consisting of prophylactically treated, mostly elderly orthopedic patients. The algorithm provides a safe dosing schedule for elderly postoperative patients who use low molecular weight heparin and NSAIDs concomitantly and are thus at high risk for bleeding complications.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 27 条
  • [21] A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis
    Romera, A.
    Cairols, M. A.
    Vila-Coll, R.
    Marti, X.
    Colome, E.
    Bonell, A.
    Lapiedra, O.
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2009, 37 (03) : 349 - 356
  • [22] Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial
    Carcas, Antonio J.
    Borobia, Alberto M.
    Velasco, Marta
    Abad-Santos, Francisco
    Quintana Diaz, Manuel
    Fernandez-Capitan, Carmen
    Ruiz-Gimenez, Nuria
    Madridano, Olga
    Llamas Sillero, Pilar
    TRIALS, 2012, 13
  • [23] Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial
    Antonio J Carcas
    Alberto M Borobia
    Marta Velasco
    Francisco Abad-Santos
    Manuel Quintana Díaz
    Carmen Fernández-Capitán
    Nuria Ruiz-Giménez
    Olga Madridano
    Pilar Llamas Sillero
    Trials, 13
  • [24] Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy
    Kumano, Osamu
    Suzuki, Shinya
    Yamazaki, Masako
    An, Yoshimori
    Yasaka, Masahiro
    Ieko, Masahiro
    THROMBOSIS RESEARCH, 2022, 210 : 87 - 90
  • [25] High pre-stroke CHADS2 score predicts unfavorable functional outcome in acute cardioembolic stroke patients prescribed oral anticoagulant therapy: A sub-analysis of the PASTA registry study
    Sakai, Kenichiro
    Suda, Satoshi
    Iguchi, Yasuyuki
    Abe, Arata
    Yagita, Yoshiki
    Kanzawa, Takao
    Okubo, Seiji
    Fujimoto, Shigeru
    Kimura, Kazumi
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (02)
  • [26] Efficacy and safety of basal-bolus insulin at 1:1.5 ratio compared to 1:1 ratio using a weight-based initiation and titration (WIT2) algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study
    Xiaodan Zhang
    Dewen Yan
    Tao Du
    Yunjuan Zhao
    Jiangong Zhang
    Tong Zhang
    Mingrun Lin
    Yanli Li
    Wangen Li
    Diabetology & Metabolic Syndrome, 15
  • [27] Efficacy and safety of basal-bolus insulin at 1:1.5 ratio compared to 1:1 ratio using a weight-based initiation and titration (WIT2) algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study
    Zhang, Xiaodan
    Yan, Dewen
    Du, Tao
    Zhao, Yunjuan
    Zhang, Jiangong
    Zhang, Tong
    Lin, Mingrun
    Li, Yanli
    Li, Wangen
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)